OMER - Omeros Corporation

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
19.50
+0.17 (+0.88%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close19.33
Open19.41
Bid0.00 x 0
Ask0.00 x 0
Day's Range19.30 - 19.64
52 Week Range7.20 - 27.09
Volume366,848
Avg. Volume699,166
Market Cap934M
Beta3.86
PE Ratio (TTM)-13.31
EPS (TTM)-1.47
Earnings DateNov 7, 2017 - Nov 13, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est38.60
Trade prices are not sourced from all markets
  • Business Wire2 days ago

    Omeros Announces Upcoming Presentation of Clinical OMS721 Data at European Society for Blood and Marrow Transplantation

    Omeros Corporation today announced that data will be presented from the company’s Phase 2 clinical trial of OMS721, Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 , for the treatment of thrombotic microangiopathies .

  • ACCESSWIRE9 days ago

    Today's Research Reports on Stocks to Watch: Omeros Corporation and Therapix Biosciences

    NEW YORK, NY / ACCESSWIRE / October 9, 2017 / Shares of Omeros Corporation pulled back on Friday but was a big winner last Thursday when the company announced it had reached an agreement with Endo International ...

  • What You Must Know About Omeros Corporation’s (OMER) Risks
    Simply Wall St.11 days ago

    What You Must Know About Omeros Corporation’s (OMER) Risks

    If you are a shareholder in Omeros Corporation’s (NASDAQ:OMER), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of your portfolioRead More...

  • MarketWatch13 days ago

    Omeros shares surge 10% after settlement with Endo delays generic to 2032

    Omeros Corporation shares surged as much as 10% in morning trade Thursday, before paring some gains, after the company announced a settlement with Endo International PLC's Par Pharmaceutical Inc. that ...

  • Business Wire13 days ago

    Omeros Announces Settlement of Infringement Suit Against ANDA Filer Par

    Omeros Corporation  today announced that it entered into a settlement agreement with Par Pharmaceutical, Inc. and its subsidiary Par Sterile Products, LLC , resolving Omeros’ patent litigation against Par.

  • Capital Cube15 days ago

    ETFs with exposure to Omeros Corp. : October 3, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Omeros Corp. Here are 5 ETFs with the largest exposure to OMER-US. Comparing the performance and risk of Omeros Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • 3 Stocks Up 30% or More Year to Date That Could Be Just Getting Started
    Motley Fool20 days ago

    3 Stocks Up 30% or More Year to Date That Could Be Just Getting Started

    These stocks are already beating the market, but don't take profits just yet.

  • Capital Cube26 days ago

    ETFs with exposure to Omeros Corp. : September 22, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Omeros Corp. Here are 5 ETFs with the largest exposure to OMER-US. Comparing the performance and risk of Omeros Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cubelast month

    ETFs with exposure to Omeros Corp. : September 12, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Omeros Corp. Here are 5 ETFs with the largest exposure to OMER-US. Comparing the performance and risk of Omeros Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cube2 months ago

    ETFs with exposure to Omeros Corp. : August 31, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Omeros Corp. Here are 5 ETFs with the largest exposure to OMER-US. Comparing the performance and risk of Omeros Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Omeros Corp. :OMER-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017
    Capital Cube2 months ago

    Omeros Corp. :OMER-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017

    Categories: Yahoo FinanceGet free summary analysis Omeros Corp. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Omeros Corp. – Pfizer Inc., BioTime, Inc., Johnson & Johnson, Acura Pharmaceuticals, Inc., Akorn, Inc., DURECT Corporation and Pain Therapeutics, Inc. (PFE-US, BTX-US, JNJ-US, ACUR-US, AKRX-US, DRRX-US and PTIE-US) ... Read more (Read more...)

  • Business Wire2 months ago

    Omeros Responds to Statnews.com Story

    Omeros Corporation stated today that it continues to pursue legal action to hold responsible those behind a series of defamatory reports about the company posted online under the pseudonym “Art Doyle,” an entity or group that self-identifies as having a short position in Omeros’ stock.

  • TheStreet.com2 months ago

    Omeros Shares Lower After Completing Stock Offering, Juno Dips - Biotech Movers

    The Seattle firm said Aug. 21 it completed an underwritten public offering of 3 million shares priced at $22.75 apiece.

  • Omeros Corp. breached its 50 day moving average in a Bearish Manner : OMER-US : August 22, 2017
    Capital Cube2 months ago

    Omeros Corp. breached its 50 day moving average in a Bearish Manner : OMER-US : August 22, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Omeros Corp.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)

  • Business Wire2 months ago

    Omeros Closes $68.3 Million Public Offering of Common Stock

    Omeros Corporation today announced that on August 18, 2017, as scheduled, it closed the underwritten public offering that was priced on August 14, 2017, relating to the sale of 3,000,000 shares of its common stock at a price to the public of $22.75 per share.

  • MarketWatch2 months ago

    Omeros's stock sinks after share offering prices at a discount

    Shares of Omeros Corp. sank 8% in morning trade Tuesday, after the biopharmaceutical company took advantage of a recent surge in price to launch a public offering of shares. The company said late Monday ...

  • Business Wire2 months ago

    Omeros Announces Pricing of Public Offering of Common Stock

    Omeros Corporation , a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system, announced today the pricing of its previously announced underwritten public offering of 3,000,000 ...

  • Business Wire2 months ago

    Omeros Announces Public Offering of Common Stock

    Omeros Corporation , a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system, today announced that it has commenced a registered underwritten public offering of 3,000,000 ...

  • Business Wire2 months ago

    Omeros Data Show Continued Improvement in Patients with IgA Nephropathy Treated with OMS721

    Omeros Corporation  today announced additional follow-up data from patients with immunoglobulin A nephropathy treated with OMS721 in the Phase 2 clinical trial of glomerulonephropathy.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of OMER earnings conference call or presentation 8-Aug-17 8:30pm GMT

    Q2 2017 Omeros Corp Earnings Call

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: Omeros Corporation and Zynerba Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / August 10, 2017 / Disappointing quarterly results combined with rising geopolitical tensions Wednesday to pressure U.S. markets lower on Wednesday. On Wednesday, North Korean ...

  • Business Wire2 months ago

    Omeros to Present at the 2017 Wedbush PacGrow Healthcare Conference

    Omeros Corporation , a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system, today announced that Gregory A.

  • Associated Press2 months ago

    Omeros reports 2Q loss

    The Seattle-based company said it had a loss of 33 cents per share. Losses, adjusted for non-recurring costs, were 23 cents per share. The drug developer posted revenue of $17.2 million in the period. ...

  • Business Wire2 months ago

    Omeros Corporation Reports Second Quarter 2017 Financial Results

    Omeros Corporation , a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for